Written and medically reviewed by Dorcas Morak, Pharm.D
The GLP-1 medication landscape changed dramatically in late 2025 and early 2026 with the arrival of the first oral weight-loss medications and new delivery formats for injectable therapies. For patients considering these treatments, one question often comes first: What will this actually cost?
Between the oral Wegovy pill, Eli Lilly's Foundayo, the updated Zepbound KwikPen, insurance coverage variations, manufacturer savings programs, and self-pay pricing options, understanding your costs is just as important as selecting the right medication. Here's what patients should know about the newest GLP-1 weight-loss treatments and their pricing in 2026.
What Are GLP-1 Medications and How Do They Promote Weight Loss?
GLP-1 receptor agonists mimic a naturally occurring hormone that helps regulate appetite, slows stomach emptying, and signals feelings of fullness. When combined with healthy eating habits and physical activity, these medications can support significant and sustained weight loss.
Several FDA-approved GLP-1 medications are now available for weight management, including:
- Semaglutide (Wegovy)
- Tirzepatide (Zepbound)
- Orforglipron (Foundayo)
While Wegovy and Foundayo work through the GLP-1 pathway, Zepbound targets both GLP-1 and GIP receptors, which may contribute to greater weight-loss outcomes for some patients.
Wegovy Pill Pricing in 2026: How Much Does Oral Semaglutide Cost?
The FDA approved oral semaglutide (Wegovy pill) in December 2025, making it the first oral GLP-1 medication approved specifically for chronic weight management.
Self-pay pricing starts at approximately:
- $149 per month for lower doses
- Up to $299 per month for higher doses
Eligible commercially insured patients may pay as little as $25 per month through manufacturer savings programs.
One important consideration is administration. The Wegovy pill must be taken first thing in the morning on an empty stomach with no more than four ounces of water, followed by a 30-minute wait before eating, drinking, or taking other medications.
Foundayo vs. Wegovy Pill: What's the Difference?
Foundayo (orforglipron), approved in April 2026, introduced a new option for patients who prefer an oral medication but want greater flexibility.
Unlike oral Wegovy, Foundayo can be taken at any time of day without food or water restrictions.
The medication is available in six dosage strengths ranging from 0.8 mg to 17.2 mg, allowing patients to gradually increase dosing and potentially minimize gastrointestinal side effects.
Clinical trial results from the ATTAIN-1 study demonstrated average weight loss of approximately 12% to 15% at higher doses over 72 weeks.
Foundayo Cost With and Without Insurance
Foundayo launched through LillyDirect with pricing that starts around:
- $149 per month for introductory doses
- Up to $349 per month for higher doses
Patients who refill within designated program timelines may qualify for lower ongoing refill pricing.
Eligible commercially insured patients may pay as little as $25 per month through manufacturer savings programs.
The Centers for Medicare & Medicaid Services (CMS) announced that eligible Medicare beneficiaries will have access to certain GLP-1 medications for approximately $50 per month beginning July 1, 2026, through December 31, 2027. Eligibility requirements and covered medications may vary, so beneficiaries should confirm coverage details directly with their Medicare Part D plan.
Home delivery options are available through LillyDirect.
Zepbound KwikPen Pricing and Self-Pay Programs
In January 2026, the FDA approved the Zepbound KwikPen, a multi-dose pen that contains a month's supply of once-weekly injections in a single device.
Through LillyDirect self-pay programs, pricing generally starts around:
- $299 per month for lower doses
- Up to $449 per month for higher doses
Without manufacturer programs, retail pricing may exceed $1,000 per month.
For many patients, comparing available pricing programs can make a substantial difference in monthly costs.
Wegovy, Foundayo, and Zepbound at a Glance
Each medication offers distinct advantages depending on a patient's goals, preferences, and budget.
Wegovy (semaglutide)
- GLP-1 receptor agonist
- Available as an injectable and oral medication
- Oral version requires fasting administration
- Self-pay programs start around $149 per month
Foundayo (orforglipron)
- Oral GLP-1 receptor agonist
- No food or water restrictions
- Self-pay programs start around $149 per month
- Average weight loss of approximately 12% to 15% in clinical trials
Zepbound (tirzepatide)
- Dual GIP/GLP-1 agonist
- Once-weekly injectable medication
- Produces the highest average weight-loss outcomes among currently approved therapies
- Self-pay programs start around $299 per month
Common Side Effects of Wegovy, Foundayo, and Zepbound
Like most GLP-1 medications, these treatments share similar side-effect profiles.
Common side effects include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach discomfort
- Decreased appetite
Symptoms are often most noticeable during dose increases and may improve as the body adjusts.
All GLP-1 medications carry warnings regarding potential thyroid C-cell tumors observed in animal studies and are generally not recommended for patients with:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
Patients with a history of pancreatitis should discuss risks with their healthcare provider before starting therapy.
Does Insurance Cover GLP-1 Medications for Weight Loss?
Insurance coverage remains one of the biggest challenges for patients seeking GLP-1 medications.
Coverage varies widely by plan. Some insurers cover obesity medications, while others require prior authorization, step therapy, or exclude weight-loss treatments entirely. Even when coverage is available, out-of-pocket costs can vary significantly depending on deductibles, copays, and formulary placement.
Medicare coverage for GLP-1 medications continues to evolve. The Centers for Medicare & Medicaid Services (CMS) announced that eligible Medicare beneficiaries will have access to certain GLP-1 medications for approximately $50 per month beginning July 1, 2026, through December 31, 2027. Eligibility requirements and covered medications may vary, so beneficiaries should verify coverage details directly with their Medicare Part D plan.
Before filling a prescription, patients should:
- Verify formulary coverage
- Confirm prior authorization requirements
- Review manufacturer savings programs
- Compare insurance costs against self-pay pricing options
In some cases, manufacturer direct-pay programs or self-pay options may cost less than using insurance. Taking a few minutes to compare all available pricing channels can help patients avoid unexpected costs and find the most affordable option.
How to Save Money on GLP-1 Weight Loss Medications
For patients paying out of pocket, comparison shopping is essential.
Manufacturer programs such as LillyDirect and NovoCare may provide reduced pricing for eligible patients, but costs can still vary depending on dosage, pharmacy, and insurance status.
The RxLess® Assurance Plan helps consumers compare prescription prices at more than 70,000 pharmacies nationwide. While the RxLess® Assurance Plan generally does not provide significant savings on brand-name GLP-1 medications such as Wegovy and Zepbound, it can help patients find lower prices on certain prescription weight-loss medications and other commonly prescribed therapies.
For example, patients may find savings on:
- Phentermine, a commonly prescribed oral weight-loss medication
- Metformin
- Bupropion
- Naltrexone
- Topiramate
Always compare all available pricing options before filling a prescription.
What About Compounded GLP-1 Medications?
Some patients may encounter advertisements for compounded semaglutide or compounded tirzepatide products.
Patients should understand that compounded medications are not FDA-approved and may carry additional risks related to quality, potency, and dosing consistency. The FDA has issued warnings regarding certain compounded GLP-1 products.
Patients considering compounded medications should discuss potential risks and benefits with their healthcare provider.
Which GLP-1 Medication Is Right for You?
There is no one-size-fits-all answer when it comes to weight-loss medications.
Patients seeking maximum average weight loss may be drawn to Zepbound, while those looking to avoid injections may prefer oral options such as Wegovy or Foundayo. Cost, insurance coverage, side effects, medical history, and lifestyle preferences all play an important role in selecting the most appropriate therapy.
A healthcare provider familiar with your medical history can help determine which medication is the best fit for your individual needs.
Important: Weight-loss medications are not appropriate for everyone. Patients should discuss potential risks, benefits, side effects, and treatment goals with a healthcare provider before starting any GLP-1 medication.
Pricing and savings programs are subject to change. Patients should verify current costs directly with manufacturers, pharmacies, and their insurance plans.
